Viatris Inc. (VTRS) is in the middle of multiple securities fraud lawsuits represented by various law firms. Investors who have experienced losses have been urged to get in touch with the respective law firms. However, on the upside, Viatris has announced excellent results for Q1, beating earnings and revenue estimates, which saw the stock price rise by 8%. Results from the Phase 3 study of XULANE LO™, the company's low dose patch for birth control, have been announced and pointed out with a positive outcome. In addition, Viatris had a successful late-stage trial win, which saw a rise in its stock value. Despite a forecast decline in earnings, one of the highlights includes being chosen as a top stock pick by billionaire Ken Fisher and the release of their sustainability report showing progress made in sustainable access to medicine. The company has confirmed its guidance for 2025 and is expected to present at the BofA Securities 2025 Healthcare Conference.
Viatris VTRS News Analytics from Mon, 27 Feb 2023 08:00:00 GMT to Sat, 17 May 2025 22:43:12 GMT -
Rating -2
- Innovation 0
- Information 5
- Rumor -6
